Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kalvista Pharmaceuticals Inc

14.86
+1.249.10%
Post-market: 14.74-0.1200-0.81%19:05 EST
Volume:3.07M
Turnover:44.09M
Market Cap:751.12M
PE:-3.77
High:14.97
Open:13.48
Low:13.32
Close:13.62
52wk High:17.28
52wk Low:7.30
Shares:50.55M
Float Shares:27.81M
Volume Ratio:1.57
T/O Rate:11.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9460
EPS(LYR):-3.6945
ROE:-190.18%
ROA:-60.98%
PB:18.41
PE(LYR):-4.02

Loading ...

KalVista Pharmaceuticals Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 11

Kalvista Pharmaceuticals Highlights EKTERLY Oral Treatment Advances for Hereditary Angioedema in New Presentation

Reuters
·
Nov 11

KalVista Pharmaceuticals reports $13.7 million in net product revenue for third quarter

Reuters
·
Nov 11

Kalvista Pharmaceuticals Inc - Qtrly Net Loss per Share, Basic and Diluted $0.92

THOMSON REUTERS
·
Nov 11

Kalvista Pharmaceuticals Inc - Net Product Revenue $13.7 Mln in Q3

THOMSON REUTERS
·
Nov 11

Top News Today/Canada: Barrick's Interim CEO Gets to Work

Dow Jones
·
Nov 11

KalVista Unveils New Data Showing High Patient Satisfaction With Oral HAE Drug EKTERLY

Reuters
·
Nov 06

KalVista Pharmaceuticals to Present at Stifel Healthcare Conference

Reuters
·
Nov 05

Kalvista Pharmaceuticals Inc. to Release Third Quarter Financial Results

Reuters
·
Nov 03

Kalvista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025

THOMSON REUTERS
·
Nov 03

KalVista price target lowered to $29 from $36 at BofA

TIPRANKS
·
Oct 22

BofA Securities Adjusts KalVista Pharmaceuticals Price Target to $29 From $36, Maintains Buy Rating

MT Newswires Live
·
Oct 22

Kalvista Pharmaceuticals Inc : Bofa Global Research Cuts Price Objective to $29 From $36

THOMSON REUTERS
·
Oct 22

KalVista Pharmaceuticals Files Initial Statement of Beneficial Ownership for Chief Operations Officer Arif Bilal

Reuters
·
Oct 09

KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema

Reuters
·
Oct 07

KalVista Pharmaceuticals Appoints Bilal Arif as COO and Linea Aspesi as Chief People Officer Amid Global EKTERLY Launch

Reuters
·
Oct 06

Kalvista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer

THOMSON REUTERS
·
Oct 06

KalVista Pharmaceuticals Grants Stock Options to New Employees Under Inducement Equity Incentive Plan

Reuters
·
Oct 03

KalVista Pharmaceuticals Appoints Bethany L. Sensenig to Board of Directors and Audit Committee

Reuters
·
Oct 02

Kalvista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors

THOMSON REUTERS
·
Oct 02